ABVX Similar Chart Price Prediction
The price of ABVX is predicted to go up 0.83%, based on the high correlation periods with SOHO. The similarity of these two price pattern on the periods is 98.63%.
ABVX
SOHO
Up: 0.83%Similarity: 98.63%
ABVX Revenue Forecast
ABVX EPS Forecast
ABVX FAQs
What is ABVX revenue forecast for next quarter？
ABVX Analyst's Forecast
Jason Butler
JMP Securities
Buy
2024-12-04
Price Target
$33
Upside
+268.72%
JMP Securities initiated coverage of Abivax with an Outperform rating and $33 price target. Abivax is focused on the development and commercialization of obefazimod, a novel immune modulator for the treatment of inflammatory bowel diseases, the analyst tells investors in a research note. The firm says the company has demonstrated "robust" Phase 2b results in patients with moderate-to-severe ulcerative colitis and results from two Phase 3 induction trials are anticipated in early Q2 of 2025. It believes the commercial potential for obefazimod is "compelling."
